Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

ClinOne Offers Complimentary Support to Researchers Racing to Develop the Coronavirus or COVID-19 Vaccine

The focal point of the initial outbreak was the Huanan Seafood Wholesale Market and the ingestion of common meals such as bat and snake; however, the zoonotic origin was quickly dispelled when more cases were identified outside of the market area and into other Chinese provinces, confirmation of person-to-person transmission, and utilization of medical imaging. To date, there are 79,360 confirmed cases worldwide, 2,619 associated deaths, and 24,963 cases that have recovered (Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE, 23 February 2020).

The first confirmed death from COVID-19 occurred on 09 January 2020 and marked the beginning of the race to create a vaccine that will treat and prevent the ill effects of this coronavirus. Several pharmaceutical companies, the U.S. National Institute of Allergy and Infectious Diseases, Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI), and a host of others have begun researching the cure; some are preparing for animal testing, and others are developing novel approaches to vaccine development. “Any vaccine will likely require human testing before final approval is awarded, and disease prevention can be achieved,” said Dr. Elizabeth Esterl, RN, VP of Operations and Research. “I am honored and humbled to offer the services of ClinOne to researchers worldwide. We are willing to assist in any way possible to stop the spread of this virus and associated deaths,” said Esterl, who has spent her career managing research institutions, including Colorado Children’s Hospital and National Jewish Health.

ClinOne offers the ability for researchers to connect directly to the patients, consent remotely, monitor symptoms of adverse reactions with wearable devices, and connect the sponsor, research sites and patients to ensure compliance and enhance the user experience. ClinOne is offering its support to accelerate the process of COVID-19 vaccine development to pharmaceutical companies by providing its clinical trial management technologies complimentary. “We are at an unprecedented time with managing the COVID-19 coronavirus outbreak around the world, and pharmaceutical partners are urgently needed to research and develop viable treatment options. We are here to support their efforts by providing the ClinOne suite of technologies free of charge,” said Rob Bohacs, CEO.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy